Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Carboplatin. Found 37 abstracts

no pagination
Feliciano JL, Le-Rademacher JG, Gajra A, Edelman MJ, Zemla T, McMurray R, Chen H, Hurria A, Muss H, Cohen HJ, Lilenbaum R, Jatoi A. Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). Journal of geriatric oncology. 2018 Sep;9(5):501-6.   PMCID: PMC6233872
Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol. 2017 Aug;40(4):393-8.   PMCID: PMC5026539
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):779-91.   PMCID: PMC5715461
Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE. Phase III Randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance). Journal of Clinical Oncology. 2017 Jul;35(19):2184-92.   PMCID: PMC5493050
Xu MJ, Chu C, Rubin S, Lin LL. Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma. Am J Clin Oncol. 2017 Dec;40(6):598-604.   PMCID: PMC4733581
Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. The New England journal of medicine. 2016 Feb 25;374(8):738-48.   PMCID: PMC5081077
Chan JK, Java JJ, Fuh K, Monk BJ, Kapp DS, Herzog T, Bell J, Young R. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials. Gynecol Oncol. 2016 Dec;143(3):490-5.   PMCID: PMC5728987
Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia S. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Sep;34(25):2969-79.   PMCID: PMC5569693
Qin T, Si J, Raynal NJ, Wang X, Gharibyan V, Ahmed S, Hu X, Jin C, Lu Y, Shu J, Estecio MR, Jelinek J, Issa JP. Epigenetic synergy between decitabine and platinum derivatives. Clinical epigenetics. 2015 Jan;7(1):97.   PMCID: PMC4567801
Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. J Clin Oncol. 2015 Apr 06;33(17):1895-901.   PMCID: 4451172
Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, Benner RJ, Scranton JR, Olszanski AJ, Jassem J. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2014 Jul;32(19):2059-66.   PMCID: Pmc4067944
Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res. 2014 Jun;20(11):3023-32.   PMCID: Pmc4049169
Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol. 2014 Jan;25(1):132-8.   PMCID: No NIH funds
Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009 Mar 20;27(9):1419-25.   PMCID: PMC 2668552
Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008 Nov;3(11):1286-92.
Langer CJ. Resectable non-small cell lung cancer in the elderly: is there a role for adjuvant treatment?. Drugs Aging. 2008 Jan;25(3):209-18.
Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6):623-30.
Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ, Gynecologic Oncology G. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol. 2008 Sep;110(3):329-35.   PMCID: PMC2577579
Sarna L, Swann S, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Byhardt R, Wasserman T, Movsas B. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys. 2008 Dec;72(5):1378-84.
Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol. 2006 Oct;103(1):1-6.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Carboplatin

Carboplatin Antineoplastic Combined Chemotherapy Protocols administration & dosage Female Middle Aged therapeutic use Paclitaxel drug therapy Aged pathology Disease-Free Survival Neoplasm Staging Adult Lung Neoplasms adverse effects Male Survival Rate Non-Small-Cell Lung Carcinoma metabolism Ovarian Neoplasms Treatment Outcome 80 and over Aged therapy mortality surgery Kaplan-Meier Estimate Monoclonal Antibodies Peritoneal Neoplasms Deoxycytidine Drug Administration Schedule analogs & derivatives Cohort Studies Intravenous Infusions Cisplatin Proportional Hazards Models dosage genetics adverse Bevacizumab effects Prognosis Epidermal Growth Factor Receptor Pemetrexed methods Polyglutamic Acid Local Neoplasm Recurrence Parenteral Infusions Cytoreduction Surgical Procedures Adenocarcinoma Fallopian Tube Neoplasms physiology administration & Antineoplastic Agents Squamous Cell Carcinoma Neoadjuvant Therapy Glandular and Epithelial Neoplasms Retrospective Studies Adjuvant Chemotherapy biosynthesis Quality of Life Chemoradiotherapy Monoclonal Antibodies-Humanized Endometrioid Carcinoma derivatives Combined Modality Therapy Clear Cell Adenocarcinoma Cystic Neoplasms-Mucinous-and Serous Mutation Small Cell Carcinoma Radiation-Protective Agents Cyclooxygenase 2 Maximum Tolerated Dose Intention to Treat Analysis Socioeconomic Factors Older patients axitinib drug Age Factors epidemiology Survival Analysis Gene Expression Profiling Endometrial Neoplasms Amifostine Induction Chemotherapy Chemotherapy Multivariate Analysis Axitinib enzymology Proto-Oncogene Proteins p21(ras) Mitogen-Activated Protein Kinase Kinases Tumor suppressor genes trends Lung cancer Weight Loss Signal Transduction Salvage Therapy BRCA2 Protein B7-H1 Antigen Piperidines Dinoprostone Young Adult Drug Interactions chemotherapy Follow-Up Studies DNA methylation Randomized Controlled Trials as Topic secondary ras Proteins Celecoxib Tissue Array Analysis Imidazoles Phosphatidylinositol 3-Kinases 5-aza-2'-deoxycytidine Benzamides Drug Dose-Response Relationship Feasibility Studies Indazoles physiopathology Deglutition Phase III Clinical Trials as Topic Radiotherapy Double-Blind Method Triple Negative Breast Neoplasms Hysterectomy Molecular Targeted Therapy Quinazolines non-squamous Survival Fluorouracil Neoplasm Drug Resistance United States Neutropenia non-small-cell lung cancer bevacizumab Biological Tumor Markers Genomic Instability Head and Neck Neoplasms Abdominal Neoplasms Doxorubicin analogs & Fluorescent Antibody Technique Time Factors Esophagectomy Brachytherapy Polyethylene Glycols chemically induced analysis Tumor Burden Bronchiolo-Alveolar Adenocarcinoma radiotherapy
Last updated on Friday, August 14, 2020